BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Leukocyte
,
Autoimmunity
,
Ciprofibrate
,
rs2476601
,
IL1A
,
calcium channel activity
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
onchocerciasis ocular
(phenotype)
Summary
General Info
Genetic Markers
Most Correlated Genes
Most Correlated SNPs
No genes found
No SNPs found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
Canine ocular onchocerciasis in New Mexico: Risk factors for disease.
Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug …
A new key-player for onchocerciasis elimination.
A Much-Needed Advance in the Diagnosis of River Blindness.
Onchocerciasis (river blindness): larva-induced eczema (onchodermatitis) from an important oculocuta…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Safety and Efficacy of IDA for Onchocerciasis
Emodepside Phase II Trial for Treatment of Onchocerciasis
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ